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TRANSLATIONAL ASSESSMENT OF PRIMARY TUMOR-DERIVED CELLS 
ERIC L. WU 
ABSTRACT 
Only a few individual cells within less than 5% of all primary tumors form the 
cell lines commonly used in cancer research. These growth bottlenecks result in cell lines 
that are often poor models of primary tumors. Co-culture of primary tumor-derived cells 
with an irradiated mouse fibroblast feeder layer and ROCK inhibitor, known as the 
Georgetown Method, offers a way to culture over 80% of tumor-derived cells in vitro to 
create more representative tumor cell models. In our studies, we optimized the 
Georgetown Method to culture head and neck cancer cells, including oropharyngeal 
squamous cell carcinoma, and investigated its mechanism of conditionally immortalizing 
cells in culture. Differential trypsinization and regular feeder layer replacement were 
found to significantly improve the efficacy of immortalizing co-cultured cells at both 
atmospheric and physiological oxygen levels. Medium conditioned by irradiated 
fibroblasts can also substitute for direct co-culture with a feeder layer. The Georgetown 
Method was found to maintain low levels of p16 in co-cultured cells, suggesting a 
potential mechanism by which the Georgetown Method prevents differentiation and 
senescence. Our ability to culture over 80% of primary tumor-derived cells allows us to 
test the translational value of tumor-derived cell cultures and xenografts using BH3 
profiling. Conditioned medium simplifies maintenance of cell cultures and will also allow 
us to perform high-throughput screens without the need to separate tumor-derived cells 
	  	   vii 
from the fibroblast feeder layer. The Georgetown Method provides opportunities to 
expand small tissue specimens for future diagnostics, therapeutics, and biobanking. 
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INTRODUCTION 	  
 Cancer remains a leading cause of death worldwide despite our increased 
understanding of cancer biology and continued advances in diagnostics and therapies. It 
is estimated that 2 out of every 5 people will be diagnosed with cancer at some point in 
their lifetime, and rates of cancer are rising as people live longer. While our increased 
understanding and treatment of cancer has significantly reduced mortality in some 
cancers like those of the breast and prostate, the prognoses for others like pancreatic 
cancer, which has a five-year survival rate of about 6%, remain poor (“WHO | Cancer” 
2013; “Cancer of the Pancreas - SEER Stat Fact Sheets” 2013).  
Cancer occurs when normal cells in the body, which regularly undergo mitosis to 
replace older cells, accumulate genetic mutations over time in a stepwise fashion as a 
result of errors during DNA replication, external mutagens such as radiation, or viral and 
bacterial infections that lead to unregulated growth and immortalization (Nowell 1976). 
Mutations that impart fitness advantages to subclones within a tissue population continue 
to be passed on because they expand and outcompete other cells for limited space and 
resources in a Darwinian-like system of natural selection (Merlo et al. 2006). If enough 
driver mutations, mutations that confer growth advantages and promote tumor 
progression, accumulate within particular subclones to achieve what Douglas Hanahan 
and Robert Weinberg call “the hallmarks of cancer,” these subclones can become 
neoplastic and form tumorigenic masses (Hanahan and Weinberg 2011). Tumors can 
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obstruct and impede normal organ function or metastasize to distant organs to form 
secondary tumors elsewhere in the body (Greaves and Maley 2012). 
 
CURRENT CANCER THERAPY 
Chemotherapy and radiotherapy are commonly used in treatment regimens for 
many types of cancers. Chemotherapeutics target rapidly dividing cells like cancer but do 
so with a variety of mechanisms including alkylating agents that damage DNA directly 
and antimetabolites that act as nucleoside analogs to substitute for the building blocks of 
DNA. Radiotherapy, like chemotherapy, can directly damage DNA or create free radicals 
that in turn damage cells and induce apoptosis. However, these treatment regimens, while 
killing off highly proliferative cancer cells, will also damage normal rapidly dividing 
cells like those that line the intestines, blood-producing cells, or hair follicles, resulting in 
adverse side effects such as nausea, anemia, and hair loss.  
Genetic variations between tumors from the same tissue of origin can result in 
markedly different responses to the same therapy regimen (Gottesman 2002). Known as 
intertumor heterogeneity, differences between tumors often result in some tumors 
displaying resistance to first-line drugs. On an even smaller scale, high intratumor 
heterogeneity within an individual tumor can also result in a wide range of drugs 
responses among clones isolated from the same tumor. In highly heterogeneous 
multiclonal tumors, a therapy regimen will often kill off sensitive clones within a specific 
tumor but select for those that may be less sensitive or resistant, resulting in cancer 
recurrence and treatment failure (Barranco et al. 1988).  
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Tumor heterogeneity and adverse side effects continue to spur cancer research 
towards more effective and less toxic therapies. This includes advances in diagnostics to 
identify early-stage cancers and discoveries of new biomarkers, specific mutations that 
may drive the tumor or confer resistance. Once these mutations can be identified on a 
patient-to-patient basis, personalized therapies can avoid damaging normal cells by more 
precise targeting of neoplastic cells. Biomarkers can help improve efficacy of treatment 
by indicating disease severity and whether a therapy regimen should be intensified or 
deintensified.  
The future of cancer treatment is racing towards personalized medicine in which 
each patient has an individualized treatment regimen that maximizes treatment efficacy 
and minimizes unwanted side effects. New discoveries in diagnostics, mechanisms, and 
drug targets are the steps towards realizing these goals. 
 
CANCER CELL LINES 
HISTORY 
While cancer is a disease that occurs in complex organisms like humans, studying 
cancer within the human body is often difficult due to the inability to conduct high-
throughput screens or interventional studies. In the early part of the 20th century, there 
was a concerted effort to develop human cell lines, a powerful tool to study cells from the 
body in the laboratory in a more accessible manner. There were thousands of attempts to 
create cell lines, but nearly all survived for only a few weeks at most (Masters 2002). In 
1951 however, George Gey successfully cultured cells from a cervical tumor explant 
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from a patient named Henrietta Lacks to generate HeLa cells, the first successful patient-
derived cell line (Skloot 2011). Following the success of HeLa, cell lines from nearly 
every type of cancer have since been developed and have proven to be invaluable for 
cancer and molecular biology research.  
From these cell lines, particularly HeLa, scientists have gained knowledge of 
fundamental cellular processes in both normal and abnormal tissues that have contributed 
to many clinical advances including a vaccine against polio as well as chemotherapeutic 
compounds to fight cancer (Scherer, Syverton, and Gey 1953; Eagle and Foley 1958). In 
the past quarter century, these cell lines have also aided in the identification of hundreds 
of genes that play a role in cancer development. These genes are often categorized as 
either oncogenes or tumor suppressor genes. Oncogenes are genes that have mutated to 
become permanently activated in the cell, leading to unregulated growth and division 
(Weinberg 2007). On the other hand, tumor suppressor genes normally prevent 
unregulated division by repairing DNA damage or inducing apoptosis. When mutated and 
inactivated, this inhibition of division is removed and contributes to unregulated growth 
(Weinberg 2007). A number of commonly mutated genes like TP53 and RB1 are 
involved in the progression of many types of cancer, and their corresponding proteins and 
associated downstream targets have been researched extensively (Levine, Momand, and 
Finlay 1991; Chinnam and Goodrich 2011). 
Scientists have also begun targeting corresponding proteins of commonly mutated 
genes in cancers to create novel chemotherapeutics. In the 1960s, translocation of 
chromosomes 9 and 22, known as the Philadelphia Chromosome, was found to be 
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associated with Chronic Myelogenous Leukemia (CML) and was the first malignancy to 
be linked to a genetic abnormality (Nowell 2007). The constitutively activated tyrosine 
kinase BCR-ABL fusion protein generated by the Philadelphia Chromosome was 
subsequently targeted with a tyrosine kinase inhibitor called imatinib mesylate (Gleevec) 
to create the first targeted cancer therapeutic, effectively launching the future of targeted 
anticancer drugs (Druker et al. 2001). Gleevec serves as a model of effective and 
powerful cancer treatment based on genetic abnormalities or biomarkers that continues to 
be pursued today. 
 
LIMITATIONS 
For the most part, cancer cell lines retain the driver mutations that cause primary 
tumors and thus have value in helping us understand major mutations responsible for 
cancers in vivo. However, there has been only incremental progress in translating basic 
knowledge from the laboratory to the clinic, and this may be due to subtle differences 
between cell lines and the primary tumors they attempt to model (Gillet et al. 2011). The 
difficulty and low success rate in creating cancer cell lines from primary tumors suggests 
significant selection when trying to derive cell lines from primary tumor specimens. In 
past attempts, Giard et al created 13 cell lines from 200 solid tumor specimens (6% 
success rate) (Giard et al. 1973), Sugaya et al created 15 cell lines from 570 lung cancer 
samples (2.6% success rate) (Sugaya et al. 2002), and Dangles-Marie et al created 3 cell 
lines directly from 31 colon cancer tumors (9.7% success rate) (Dangles-Marie et al. 
2007). Across all cancer types, success rates in establishing cell lines directly from 
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primary tumors have continued to remain at about 5% and usually lie on the lower end of 
the spectrum. 
Intertumor heterogeneity, or differences between tumors of the same cancer type, 
contributes significantly to the low success rate. Most cell lines seem to be derived from 
only the most highly proliferative, metastatic tumors, which fail to represent the majority 
of tumor specimens (Sugaya et al. 2002; Mehta et al. 2007). In one study examining 15 
stable cell lines derived from 570 lung cancer specimens, 11 (73%) were derived from 
stage III and IV cancers, and 10 (67%) of those patients had already died, indicating that 
a significant majority of those specimens that formed cell lines derived from the most 
aggressive, deadly tumors (Sugaya et al. 2002). Cell lines may thus be more 
representative of high-grade tumors, especially tumors composed of very proliferative 
subclones, but fail to effectively represent low and medium-grade tumors, which make up 
the majority of cancers (Dairkee et al. 2004). 
In addition to intertumor heterogeneity, intratumor heterogeneity or the variety of 
cell types within a single tumor, may also be altered by selective pressures seen during 
the creation of cell lines. Culture conditions such as monolayer culture, growing on 
plastic, and high oxygen tension select for subpopulations of cells within the tumor that 
can proliferate well in the specific culture conditions. Cell lines often result from only a 
small percentage of viable cells that are plated, and varying culture conditions would 
likely generate different cell lines. Cell lines also often differ significantly from the cell 
types that are a part of the tumor microenvironment (Gillet et al. 2011; Gillet, Varma, and 
Gottesman 2013).  
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For example, cell culture is traditionally done at atmospheric oxygen levels 
(21%), and early cell culture was often conducted on plates left on the bench top. 
Physiological oxygen levels however are lower, ranging from below 1% in the brain to 
12% in arterial blood (Panchision 2009). Research has shown that culturing cells at 
physiological oxygen levels (3%) increases plating efficiency and lifespan relative to 
cells cultured at atmospheric oxygen (Richter, Sanford, and Evans 1972; Packer and 
Fuehr 1977; Parrinello et al. 2003). Culture conditions like varying oxygen levels can 
have a significant effect on the survival of particular cells within the culture, potentially 
creating a cell line that differs greatly from the primary tumor. 
As cells are cultured long-term for many passages, the culture becomes 
increasingly homogenous as clones with the most advantageous mutations proliferate 
faster and outcompete other cells within the culture (Merlo et al. 2006). Several studies 
have analyzed similarities and differences between cell lines and the primary tumors they 
attempt to model, looking at both genomic and transcriptomic changes. Gene expression 
profiles and clustering reveal that cells lines actually resemble each other more than the 
original clinical samples they are intended to represent (Virtanen et al. 2002). These 
results were shown in several solid tumors including ovarian carcinoma (Domcke et al. 
2013), breast cancer (Mehta et al. 2007), head and neck squamous cell carcinoma (Chung 
et al. 2004), colorectal cancer (Gillet, Varma, and Gottesman 2013), and two types of 
leukemia (Gillet, Varma, and Gottesman 2013). It has also been shown that during their 
establishment, cancer cell lines highly select for genes associated with multi-drug 
resistance, which may contribute to the discrepancy seen between prognostic markers and 
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clinical results (Gillet et al. 2011). The results suggest selection and induction of genes in 
cell lines by common culture conditions, skewing their ability to represent primary 
tumors. 
These differences highlight the importance of recognizing the limitations of cell 
lines. Because selection pressures and culture conditions limit both intertumor and 
intratumor heterogeneity, the cell lines isolated from patient tumors are forced into 
bottlenecks of growth. Of the few excised primary tumors that can form a cell line, only a 
few individual cells within the entirety of the tumor ecosystem ever develop the ability to 
proliferate and create a successful cell line. These cell lines, which represent a small 
fraction of all cancer cells, are currently used to make discoveries that are applied to the 
entire spectrum of cancers. It is no surprise that they often fail to model the in vivo 
character of most tumors and often lead to failures when trying to translate findings 
therapeutically from the laboratory to patients in the clinic. Thus, there is a need to 
modify the methods we use to approach cancer research and a need to study primary 
tumor-derived cells and low-passage cell lines. 
 
PRIMARY TUMOR-DERIVED CELLS 
The key to developing a panel of cell lines that can model primary tumors 
appropriately is to maximize both intertumor heterogeneity, increasing the success rate of 
culturing primary tumors in vitro, and intratumor heterogeneity, maintaining the variety 
of cell types within the original tumor. As evidenced by the attempts to develop human 
cell lines over the past century, the majority of primary tumor-derived cells fail to 
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proliferate in vitro, differentiating and senescing after a few passages. Normal cells can 
only divide a limited number of times, which is regulated by the length of their telomeres, 
and will stop dividing, also known as replicative senescence, after this number is reached. 
DNA-damage, irradiation, or toxins can also cause cells to stop replicative division. 
Long-term cell culture depends on continuing the proliferative ability of the cell by 
preventing senescence and limiting cellular differentiation. There have been several 
methods attempted to overcome these barriers. 
One of the most common ways to immortalize primary cells has been 
transformation with viral oncogenes, such as the simian virus 40 large tumor antigen 
(SV40) or E6/E7 proteins of the oncogenic human papillomaviruses (HPV) (Bartek et al. 
1991; Hawley-Nelson et al. 1989). A common theme of cellular immortalization is the 
inactivation of the p53 and p16/Rb pathways and activation of hTERT (Rheinwald et al. 
2002). The SV40 Large T antigen and E6/E7 HPV proteins are known to activate both of 
these pathways. However, use of viral oncogenes bypasses tumor suppression 
mechanisms by inactivating the exact pathways of interest. By altering the characteristics 
of the cultured, immortalized cell, viral oncogenes also cause problems when trying to 
create an accurate in vitro model of the primary tumor (Meisner et al. 1988). 
HPV immortalizes cells partly by inducing hTERT, the catalytic subunit of human 
telomerase (Liu et al. 2008; Liu et al. 2009). Telomeres, portions of genetic code at the 
end of chromosomes, act as a buffer to prevent the chromosomal ends from deteriorating 
and have also been shown to be vital in determining the lifespan of a cell. As cells divide, 
telomeres become slightly shorter with each DNA replication, limiting the number of 
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cellular divisions to a number known as the Hayflick Limit. Many cancers, in order to 
prevent cellular senescence, induce production of telomerase, an endogenous enzyme 
usually silenced in postnatal somatic cells that extends the length of telomeres. 
Exogenous expression of hTERT has been shown to increase the lifespan and number of 
cellular divisions (Counter et al. 1998). However, similar to the use of viral oncogenes, 
induction of hTERT can cause karyotypic variations, aberrant differentiation, and 
tumorigenicity over extended passaging (Toouli et al. 2002). 
Besides viral transformation and induction of hTERT, irradiated mouse 
fibroblasts have been used as early as the 1970s as a feeder layer to support growth of 
epithelial cells, including keratinocytes (Rheinwald and Green 1975; Taylor-
Papadimitriou, Shearer, and Stoker 1977). Normal keratinocytes cultured without a 
feeder layer exhibit a bloated phenotype, positive senescence-associated β-galactosidase 
staining, and senescence-associated heterochromatin foci after just a few passages. The 
feeder layer increases the number of epidermal cell doublings in culture significantly 
from about 20 to 40-60 population doublings (PD) and helps prevent the cultured cell 
population from being overgrown with human fibroblasts (Rheinwald and Green 1975; 
Green, Rheinwald, and Sun 1977; Ramirez et al. 2001). A feeder layer was also shown to 
support colony formation from single keratinocytes (Barrandon and Green 1987). 
Although the mechanism of how irradiated fibroblasts can extend keratinocyte 
proliferation is still unknown, findings suggest that feeder cells may enhance lifespan 
partly by inducing telomerase (Fu, Quintero, and Baker 2003; Rheinwald et al. 2002). 
Besides keratinocytes, primary tumor cultures derived from breast carcinoma were also 
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supported by irradiated fibroblast feeder layers (Wang et al. 2001). Feeder layers are now 
also commonly used to produce epithelial cell layers appropriate for skin grafting for 
severely burned patients (Pellegrini et al. 1999). Although promising, cells grown on 
feeder layers are not completely immortalized and still exhibit senescence, though after 
significantly more population doublings (Bisson et al. 2013). 
Another important aspect of long-term cell culture is the prevention or limitation 
of cellular differentiation. Rho kinase (ROCK) has many roles within the cell including 
regulation of cytokinesis and cellular differentiation (Kosako et al. 2000; Sordella et al. 
2003). Large-scale death of cultured human embryonic stem (hES) cells caused by 
anoikis, or death of anchorage-dependent cells induced by loss of contact with the 
extracellular matrix, was recently prevented with the use of ROCK inhibitors (Watanabe 
et al. 2007). The use of ROCK inhibitors not only prevents apoptosis of hES cells during 
passaging but also improves recovery and colony formation after thawing from a 
cryopreserved state (Claassen, Desler, and Rizzino 2009). ROCK inhibition has also been 
effective in maintaining embryonic and induced pluripotent stem (iPS) cells in an 
undifferentiated state in culture, potentially prolonging the proliferative ability of the cell 
(Pakzad et al. 2010). 
Although some of the previous methods have proven to have some efficacy in 
primary cell culture, most of them continue to pose problems for long-term culture: 
selection of the most proliferative cell clones, eventual senescence, relying on viral 
transformation, or changing properties of the cultured cells.  
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GEORGETOWN METHOD: CONDITIONALLY REPROGRAMMED CELLS 
 FINDINGS 
In 2010, the Schlegel group at Georgetown showed that a combination of an 
irradiated Swiss 3T3-J2 mouse fibroblast feeder cell layer and the ROCK inhibitor Y-
27632 in cell culture, now known as the Georgetown Method (Figure 1), greatly 
increases the proliferative capacity of primary human keratinocytes, conditionally 
reprogramming cells to effectively immortalize them in vitro (Chapman et al. 2010). 
While both fibroblast feeder layers and ROCK inhibitors have been used in the past to 
increase the proliferative ability of cells in culture, the combination of the two allows 
both normal and neoplastic tissues to proliferate indefinitely beyond the number of 
population doublings achieved with either method independently or with other methods 
that use exogenous viral or cellular gene expression. The Schlegel group refers to cells 
immortalized by this system as conditionally reprogrammed cells (CRCs) due to the fact 
that normal differentiation is seen upon removal of the ROCK inhibitor and feeder cells, 
even after human ectocervical cells (HECs) were cultured for over 200 population 
doublings under this system (Suprynowicz et al. 2012).  
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Figure 1: Georgetown Method supports growth and immortalization of human 
epithelial cells. Following mincing and digestion, co-culture of human tissue with an 
irradiated feeder layer of Swiss 3T3-J2 fibroblasts and 10 µM ROCK inhibitor (Y-27632) 
allows cells to propagate. Small colonies of cells can be observed after 1 day, and large 
colonies of cells compress adjacent feeder cells after 5 days (white arrows) (Figure from 
Liu et al. 2012). 
 
Both the ROCK inhibitor and feeder cells appear to be necessary to immortalize 
cells. Without a ROCK inhibitor, keratinocytes cultured with feeder cells were seen to 
senesce after 20 to 40 population doublings, but with the addition of the ROCK inhibitor, 
foreskin keratinocytes were cultured for over 100 population doublings and are 
considered immortal (Chapman et al. 2010). Likewise, cells cultured in only the ROCK 
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inhibitor without a feeder layer could not bypass senescence (Chapman et al. 2010). Cells 
passaged long-term with the Georgetown Method also remain karyotypically normal, an 
important advantage this system has over other methods used to immortalize cells (Liu et 
al. 2012). 
Previously, less than 5% of primary tumors could be cultured outside of the body 
to form long-term cultures, and nonkeratinocyte epithelial cells from prostate and liver 
tissues were particularly difficult to culture and characterize (Castell and Gómez-Lechón 
2009; Miki and Rhim 2008). Using the Georgetown Method, the Schlegel group has 
successfully generated cell lines from almost 90% of biopsied specimens including 
nonkeratinocyte epithelial cells from prostate, breast, lung, and liver tissues (Table 1) 
(Liu et al. 2012). Propagation of intertumor heterogeneity with the Georgetown Method 
is thus much higher relative to previous methods of cell line creation that selected for 
only the most aggressive tumors. 
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Table 1. Georgetown Method conditionally reprograms variety of human and 
animal tissues. The Schlegel group was able to culture almost 90% of all biopsy 
specimens tested, and cell lines generated from the samples are indicated. Success is 
defined as ability of cultured cells to reach 50 population doublings, or in colon and 
pancreas, as three times the population doublings observed with current, optimal culture 
conditions (Table from Liu et al. 2012). 
  
B, BRCA 1/2 mutation carrier; H&N, head and neck cancer; met, metastatic; NA, not 
applicable; T, tumor. 
 
In addition to maximizing intertumor heterogeneity by culturing a wide variety of 
both normal and neoplastic tissues, the Georgetown Method appears to also conserve 
intratumor heterogeneity in early passages by reprogramming the entire population of 
cells within an individual tumor. By using flow cytometry to measure levels of the stem 
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cell marker integrin α6 per cell in a population of HECs over time, the Schlegel group 
found expression levels indicative of a single population of cells undergoing gradual 
reprogramming to a stem cell-like state (Suprynowicz et al. 2012). This suggests 
conservation of all cells in culture. However, it has not been determined whether the 
Georgetown Method selects for a subset of cells during initial plating. There are also 
likely still selective growth advantages between clones, and we would expect the most 
proliferative clones to outcompete other cells in the culture after extended passaging. 
The Georgetown Method thus maintains both intertumor and intratumor 
heterogeneity, at least in early passages, making it a powerful tool to culture and study 
nearly all primary cell specimens. 
 
MECHANISM 
Although the mechanism of the Georgetown Method is currently unknown, there 
are insights in to how the combination of ROCK inhibition and an irradiated fibroblast 
feeder layer is able to immortalize co-cultured cells. Rho-associated kinases, ROCK 1 
and ROCK 2, regulate many cellular processes including migration, adhesion, and 
differentiation (Amano, Fukata, and Kaibuchi 2000; McMullan et al. 2003). ROCK has 
been shown to be an important regulator of cytoskeletal changes like stress fiber 
formation, and its inhibition has the potential to inhibit cancer cell migration and 
invasion, making ROCK a target for cancer therapeutics.  
ROCK inhibition with Y-26732 has been shown to prevent terminal 
differentiation and increase cellular proliferation in keratinocytes (McMullan et al. 2003). 
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High-calcium and serum in media induces terminal differentiation of cultured cells (Pillai 
et al. 1988), but the Schlegel group has shown that ROCK inhibition in combination with 
a feeder layer may suppress differentiation usually induced by these conditions. 
(Palechor-Ceron et al. 2013). Cytoskeletal changes play a role in regulating 
differentiation and determining stratification of epidermal cells, specifically migration of 
cells within the epidermal environment and adhesive structures important for cell-to-cell 
interactions (Vaezi et al. 2002). Adult stem cells reside in deeper, more basal levels of the 
skin and migrate upwards to replenish dead cells at the surface (Blanpain and Fuchs 
2006). Disruption of this pathway through ROCK inhibition in culture could allow for 
cells to maintain their basal-like state and proliferate indefinitely. However, the 
mechanism of how the ROCK inhibitor signals the cell to prevent differentiation, 
possibly through cytoskeletal changes, remains to be elucidated.  
In addition to the ROCK inhibitor, irradiated fibroblasts are also essential for the 
conditional immortalization process. The Schlegel group recently showed that physical 
contact between CRCs and the irradiated fibroblast feeder layer is not necessary for 
conditional immortalization (Palechor-Ceron et al. 2013). The irradiated fibroblasts 
appear to release one or more diffusible factors that in combination with the ROCK 
inhibitor can promote keratinocyte proliferation and survival, and conditioned medium 
collected from cultures of irradiated fibroblasts can substitute for direct co-culture with 
the feeder layer. Previous research has shown that fibroblasts secrete glycoproteins such 
as fibronectin, laminin, and type IV collagen that could support attachment and promote 
proliferation of co-cultured cells (Alitalo et al. 1982). However, it is still unknown what 
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these diffusible factors may be or what pathways are involved for immortalization by the 
Georgetown Method.  
Research also suggests that the DNA-damage arrest and apoptosis of the feeder 
cells induced by irradiation may be essential for release of the relevant factors. Release of 
the factors appears to correlate with the onset of apoptosis following irradiation 
(Palechor-Ceron et al. 2013). Apoptotic cells are known to promote wound healing in 
surrounding tissues in vivo through the release of diffusible growth factors, and the 
process of apoptosis has been shown to be necessary to initiate regeneration in a variety 
of biological models including Xenopus tadpoles and planaria (Tseng et al. 2007; Hwang 
et al. 2004). Caspases 3 and 7, primary regulators of apoptosis, appear to regulate the 
release of arachidonic acid, a precursor of prostaglandin E2 (PGE2) (Li et al. 2010). PGE2 
is a promoter of stem cell proliferation and tissue regeneration. Whether irradiation 
specifically, senescence, or apoptosis of fibroblasts stimulates secretion of the factors that 
contribute to formation of CRCs has yet to be determined. 
Many questions regarding the mechanism of the Georgetown Method still remain. 
Primary HECs cultured with this system appear to resemble adult stem cells, exhibiting 
induction of adult epithelial stem cell markers like increased expression of ΔNp63α and 
CD-44 and decreased expression of Notch-1 signaling (Suprynowicz et al. 2012). This 
suggests that the Georgetown Method could be increasing the proliferation of cancer stem 
cells or turning on stem cell markers in cells within the culture. It is still unclear what 
diffusible factors are involved and how they, along with the ROCK inhibitor, interact 
with co-cultured cells to induce conditional immortalization. Following binding of these 
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factors, many signaling pathways regulating senescence and differentiation must also be 
activated or repressed to effect changes in the cell. The p16INK4A tumor suppressor, for 
example, is an important regulator of the cell cycle and senescence, and p16 inactivation 
is seen in almost all cancers, contributing to uncontrolled cell growth (Kim and Sharpless 
2006; Gil and Peters 2006). Because of p16’s key role in controlling senescence, ROCK 
inhibition and irradiated fibroblasts could immortalize cells through regulation of this 
pathway, making it a valuable point of study for elucidating both the mechanism of p16 
and the Georgetown method. Answering these questions about what pathways are 
important to induce cellular immortalization could lead to future cancer therapeutics that 
target players in the pathway to induce senescence in neoplastic cells and limit their 
growth. 
 
SIGNIFICANCE AND FUTURE APPLICATIONS 
APPLICATIONS OF CONDITIONALLY REPROGRAMMED CELLS 
The ability to create tumor-derived cell lines through the Georgetown Method 
represents a significant discovery for all of cancer research. Expansion of cells from 
primary tumors allows for the creation of tumor-derived cell lines that provide a much 
more representative in vitro model than cell lines currently used in the majority of cancer 
research. Recent preclinical trials of new cancer therapeutics have been a poor predictor 
of clinical success, and the high rate of failure is attributed to testing on high-passage cell 
lines that can have significantly different characteristics than primary tumors (Godoy et 
al. 2013). Low-passage tumor-derived cells limit the selective pressures of cell culture as 
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well as the potential mutations and cellular contamination that can accumulate from 
decades of passaging. Thus, these new models, which could encompass all types of 
tissue, could provide insight into driver mutations, help elucidate mechanisms of 
carcinogenesis, and offer a better model for drug discovery to increase the success rate of 
new therapeutics and improve clinical outcomes. 
With the ability to create cell lines from nearly 90% of all specimens, the 
Georgetown Method gives laboratories the power to create viable cell biobanks, frozen 
stocks of human biospecimens. These cells can be thawed and expanded when necessary, 
providing an inexhaustible supply of patient-derived specimens for study and 
experimentation. The applications of these cells are limitless. Because normal and 
neoplastic cells can both be cultured, comparative genetic and molecular analyses could 
elucidate the specific mutations that drive carcinogenesis in each individual. Addition of 
clinical data to these genetic profiles and comparison of thousands of tumors from the 
same tissue of origin will ultimately expand the value of biobanks even further by helping 
in the identification of biomarkers to stratify patients by disease severity to determine 
treatment regimen and to predict clinical outcomes, both needed for improved treatment 
of oropharyngeal squamous cell carcinomas (OPSCC), a specific type of head and neck 
cancer our laboratory is interested in. 
In the past decade, there has been a push towards personalized therapies: creating 
individualized treatment regimens for each unique tumor. More often than not, an 
individual’s response to a drug differs somewhat from the expected outcome, which is an 
averaging of drug responses after clinical trials. Using the Georgetown Method, cells 
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from a primary tumor could be isolated, expanded, and subjected to drug tests to 
determine drug resistance and toxicity before administering treatment. This eliminates the 
potential of treatment failure and limits side effects associated with most chemotherapies. 
Yuan et al have already shown the potential and power of the Georgetown Method in a 
case of recurrent respiratory papillomatosis, a disease that has no known effective 
treatment therapies (Yuan et al. 2013). Expanding tumor cells from a biopsy, the group 
used these cells to diagnose the viral infection responsible for the disease and to 
determine which drugs were most effective, allowing for treatment, tumor shrinkage, and 
cancer stabilization. It remains to be seen whether this same approach of drug screening 
using the Georgetown Method can be applied to other tumors. 
Patient-specific in vitro drug testing combined with biomarker identification is the 
key to the next wave of cancer treatments, and the ability to conditionally immortalize 
primary tumor-derived cells provides the means to achieve that dream. 
 
HEAD AND NECK CANCERS 
OPSCC, though not as prominent as some cancers like that of the breast or 
prostate, have seen a recent upswing in incidence, primarily due to the role of human 
papillomavirus (HPV) in their carcinogenesis (Chaturvedi et al. 2011). While the 
incidence of HPV-negative tumors, which are strongly associated with age, tobacco use, 
and alcohol use, has declined by 50% between 1988 and 2004 because of smoking 
cessation, incidence of HPV-positive tumors increased by 225% during the same time 
period (Applebaum et al. 2007; Chaturvedi et al. 2011). HPV-positive OPSCC cases are 
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seen in a largely different demographic than HPV-negative cancers and are associated 
with different risk factors such as decreasing age of first intercourse and increasing 
number of sex partners (Schwartz et al. 1998). HPV-positive OPSCC appears to be a 
markedly different disease due to its unique clinical presentation, lower rates of disease 
progression, and improved outcomes, suggesting the need for a new drug targets and de-
escalated treatment regimens (Bonilla-Velez et al. 2013).  
Identification of biomarkers and understanding of HPV-positive OPSCC’s unique 
pathogenesis are essential for proper treatment, but current available research is lacking 
in these areas. Because HPV-positive OPSCC is associated with improved response to 
therapy and better prognosis, there is a potential to lessen the degree of treatment to 
decrease morbidity associated with traditional treatment of OPSCC. However, the 
absence of reliable biomarkers to stratify patients by projected response or severity of 
disease highlights the need for further investigation of OPSCC and its mechanism of 
action.  Identification of important players in the pathology of OPSCC will aid in the 
development of targeted therapies like cetuximab, an antibody against epidermal growth 
factor receptor (EGFR) shown to improve quality of life for HPV-positive OPSCC 
patients, to also help limit side effects and improve treatment outcomes (Bonner et al. 
2010).  
The Schlegel group has also suggested parallels between HPV-induced 
carcinogenesis and the potential mechanism for conditional immortalization, making 
OPSCC a unique model for studying the Georgetown Method (Liu et al. 2012). HPV 
codes for two oncoproteins, E6 and E7, that target and disrupt important cellular 
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pathways, resulting in deregulation of proliferation, apoptosis resistance, immortalization, 
and transformation of infected cells. E6 and E7 also induce genomic instability to make 
the genome more susceptible to additional mutations that contribute to increased 
carcinogenesis (McLaughlin-Drubin and Münger 2009). One of the major roles of the E6 
oncoprotein is to induce hTERT, an important step in preventing telomere erosion and 
allowing a cell to proliferate indefinitely (Liu et al. 2008). The E7 oncoprotein plays a 
role in regulating the actin cytoskeleton and inactivating the p16/Rb pathway, a regulator 
of apoptosis, mitotic checkpoints, and cellular differentiation (McLaughlin-Drubin and 
Münger 2009; Yue et al. 2011). Conditional immortalization with the Georgetown 
Method could induce similar effects in CRCs including hTERT induction by feeder cells 
and actin/myosin disruption by the ROCK inhibitor, suggesting similar pathways of 
immortalization (Liu et al. 2012). Further study of both HPV-positive tumors and CRCs 
may provide insights into the mechanisms of both processes.  
The recent epidemic of oropharyngeal cancers and the role HPV has in their 
pathogenesis makes them an interesting group of cancers to study. Application of the 
Georgetown Method to OPSCC will capitalize on the observed similarities between HPV 
carcinogenesis and conditional immortalization. Because OPSCC usually manifests as 
relatively small tumors, the Georgetown Method provides a powerful tool to expand the 
number of cells available for profiling, drug testing, and further experimentation needed 
to improve diagnostics and treatment. 
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FURTHER QUESTIONS 
The two main problems of current cell lines that need to be addressed are how to 
avoid the bottlenecks during cell line creation that destroys heterogeneity and how to 
model the tumor microenvironment outside of the body. The tumor microenvironment 
has recently been discovered to be an important regulator of tumorigenesis. While tumors 
were previously thought to simply be a proliferation of neoplastic cells, current research 
suggests that the constantly evolving microenvironment within and surrounding the 
tumor contains a heterogeneous mixture of cells that are in constant communication with 
each other and their associated stroma (Quail and Joyce 2013). This microenvironment 
encompasses many cell types, some of which are not neoplastic, and a variety of 
diffusible factors like inflammatory cytokines and growth factors that influence the 
progression of the tumor. Rather than targeting the neoplastic cells themselves, there have 
been efforts to alter the tumor microenvironment instead to change promoting factors and 
enhance immunotherapy (Kershaw et al. 2013). 
To study the tumor microenvironment, patient-derived xenograft (PDX) models 
have been used to recapitulate the tumor niche. PDX models were recently developed 
from head and neck squamous cell carcinomas by surgically implanting tissue from a 
patient directly into immunocompromised mice (Peng et al. 2013). The xenografts 
maintained the histology and gene expression patterns of the original tumor better than 
cells in culture and were shown to also be useful for drug testing in vivo (Peng et al. 
2013). This could prove to be a powerful tool to not only expand and study primary cells 
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outside the body but also study them within a tumor ecosystem that plays such a large 
role in determining cancer progression.  
However, many limiting factors prevent this technique from being widely used. 
The biggest problem, like in creation of cell lines, is the low xenograft success rate with a 
preference for aggressive tumors that are poorly differentiated, node positive, and 
advanced tumors from donors with poor prognoses (Peng et al. 2013). Similarities 
between PDX models and the original tumor still remain questionable, and further 
research is needed to compare them. Mechanically, xenografts require a significant 
number of tumor cells for implantation, a limiting factor for small OPSCC cancers and 
limited tissue from head and neck cancer biopsies. Unlike in cell cultures, high-
throughput screens are difficult with xenografts due to the resources and time needed to 
inject, monitor, and care for mice. Because mice must be immunodeficient for effective 
xenografting, PDX models also eliminate the ability to investigate how the immune 
system plays a role in influencing cancer, an important point of study and therapeutic 
target. Finally, the cost of studying cancer through xenografts is much higher than simply 
studying cells in culture. 
Despite the difficulties in modeling the tumor microenvironment, the Georgetown 
Method provides a potential solution for the first problem of cell culture: selection 
associated with the creation of cell lines. The Schlegel group’s 90% success rate in 
culturing both normal and abnormal cells from a variety of tissues represents a 
breakthrough for the derivation of cell lines with many potential applications (Liu et al. 
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2012). However, remaining questions about the Georgetown Method still need to be 
addressed before it can be widely applied. 
The first is to examine whether the combination of feeder cells and ROCK 
inhibition can be replicated to support conditional immortalization of both normal and 
neoplastic cells in other labs. We have chosen to apply the protocol to head and neck 
cancers, primarily OPSCC, to see if excised tumors can be dissociated and expanded to 
establish a viable biobank for our future studies. The protocol must be optimized to 
support our patient’s tumor cells for expansion and long-term culture. 
Once the Georgetown Method can be used to create tumor-derived cell lines from 
our patient samples, we also hope to begin elucidating the mechanism for conditional 
immortalization by feeder cells and ROCK inhibition. Although p16 is known to play a 
role in cellular senescence and tumor suppression, the mechanism of p16 regulation is 
still poorly understood. Our preliminary results suggest that the combination of feeder 
cells and ROCK inhibition may be regulating p16 in some way to prevent senescence 
and/or cellular differentiation during conditional immortalization.  
 This study aims to apply and optimize the Georgetown Method for OPSCC and 
investigate the potential mechanisms of conditional immortalization. With this project, 
we hope to show that tumor-derived cell lines can serve as a representative model for in 
vivo tumors and as a valuable resource for future translational cancer research. 
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SPECIFIC AIMS 
 
 The goals of this study are to first understand how to culture and create tumor-
derived cell lines (TDCL) from OPSCC samples and delve into the mechanism of how 
the Georgetown Method immortalizes cells. Coming in to the Rocco laboratory, there 
were difficulties applying the Georgetown Method to our own patient-derived tissue 
samples to culture primary tumor-derived cells and replicate the success rate of the 
Schlegel group. Thus, the primary objective of this study is to figure out how to apply the 
Georgetown Method successfully to both normal tissue and head and neck cancer 
samples. Specifically, 
1) Growth conditions will be optimized for surgically removed oropharyngeal 
cancers to culture primary tumor-derived cells. 
2) Efficiency and efficacy of culturing tumor-derived OPSCC will be improved 
to establish conditions and plans for cell biobanking. 
3) Role and mechanism of feeder cells and ROCK inhibitor in preventing 
differentiation and senescence will be investigated. 
We hope these studies show that primary tumor-derived cells can be cultured 
effectively in vitro and be used as a representative model for future cancer studies. Once 
we can culture primary tumor-derived cells, we can analyze their translational value and 
whether tumor-derived cells cultured in the lab and in xenografts are representative of 
tumors in vivo. We also hope to begin to understand how the combination of ROCK 
inhibition and fibroblast feeder layer induces the immortalization of primary tumor-
derived cells. 
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METHODS 
Harvesting of Tissues: Tumor Dissociation 
 Normal or tumor tissue specimens were collected with the informed consent of 
patients according to a protocol (11-024H) approved by the Massachusetts Eye and Ear 
Human Studies Committee (Boston, Massachusetts). Tissues were washed with PBS 
(Sigma-Aldrich) and minced with clean razor blades. The tissue was then transferred to a 
15 ml conical containing 3 ml media [RPMI-1640 with L-glutamine (Lonza), 100 U/ml 
penicillin (Mediatech), 100 µg/ml streptomycin (Mediatech), 10 µmol/L Y-27632 (Enzo 
Life Sciences) in DMSO (Fisher Scientific)], 12 mg collagenase (Type 1, Worthington), 
and 450 U DNAse I (Sigma-Aldrich) for digestion for 1 hour at 37°C. Tissue was then 
spun down at 700 RPM. The pellet was resuspended in 1 ml trypsin-EDTA (Mediatech) 
and rocked for 5 minutes at 37°C. Viable cells were scored and the tissue was spun down 
and resuspended in 3 ml filter-sterilized F media [3:1 (v/v) Ham’s F-12 Nutrient Mixture 
(Lonza)-Dulbecco’s modified Eagle’s medium (Lonza), 5% fetal bovine serum (Sigma-
Aldrich), 0.4 µg/ml hydrocortisone (Sigma-Aldrich), 5 µg/ml insulin (Sigma-Aldrich), 10 
ng/ml epidermal growth factor (Invitrogen), 24 µg/ml adenine (Sigma-Aldrich), 8.4 ng/ml 
cholera toxin (Sigma-Aldrich), 100 U/ml penicillin (Mediatech), 100 µg/ml streptomycin 
(Mediatech), 292 µg/ml L-glutamine (Mediatech), 1 µg/ml amphotericin B (Mediatech)] 
with addition of 10 µmol/L of Y-27632 (Enzo Life Sciences). Cells were then plated on a 
60 mm dish with 200,000 irradiated (3000 rads) Swiss 3T3 fibroblasts (J2 strain). 
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Culture and Irradiation of Fibroblasts 
 Swiss 3T3 mouse embryonic fibroblasts (J2 strain, ATCC CLL-92) were cultured 
at 37°C and 21% oxygen on 24 150 mm culture dishes and 30 ml of Dulbecco’s modified 
Eagle’s medium (DMEM) (Lonza) with 10% fetal bovine serum, 100 U/ml penicillin 
(Mediatech), and 100 µg/ml streptomycin (Mediatech) per plate. Media was changed 
every 2 to 3 days. When cultures were 90% confluent, each set of 8 150 mm plates was 
trypsinized, collected, and resuspended in 40 ml of DMEM with 10% FBS and 
penicillin/streptomycin. Suspensions of cells were irradiated at 3000 rads. Irradiated cells 
were resuspended in DMEM with 5% DMSO (Fisher Scientific), and frozen in liquid 
nitrogen. Prior to use, frozen cells were thawed at 37°C and washed with F media. 
 
Cell Culture and Passaging 
 Irradiated fibroblast feeder co-culture 
 Two different culture conditions were used to propagate patient-derived cells in 
culture. The first method of culture used an irradiated mouse embryonic fibroblast feeder 
cell system for direct-contact co-culture. Approximately 200,000 irradiated 3T3 
fibroblasts were thawed and seeded on a 60 mm dish in F medium supplemented with 10 
µmol/L of the ROCK inhibitor Y-27632 unless otherwise noted. The fibroblasts were 
allowed to sit down on the plate for at least 1 hour at 37°C and 3% O2 before the tumor or 
normal cells of interest were plated on to the feeder layer. Cell cultures were maintained 
at 37°C and 3% O2 unless otherwise noted. 
	  30	  	  
When cell cultures reached 80-90% confluence, cultures were passaged. In the 
Old method (Table 3), cultures were treated with 0.25% trypsin-EDTA for 5-7 minutes at 
37°C. Cells were monitored by microscopy and detached by gentle tapping. Cells were 
collected using 3 ml of F media supplemented with 10 µmol/L of Y-27632 and a 1:30 
dilution (100 µl) was plated on to a new 60 mm culture dish with an irradiated feeder 
layer. Because cells were passaged at a 1:30 dilution, each passage was equivalent to 5 
population doublings. 
In the New method (Table 3), confluent plates were first differentially trypsinized 
with 0.05% trypsin-EDTA [filter-sterilized 0.25% trypsin-EDTA diluted with HBSS 
(Mediatech)] for 5-7 minutes at 37°C to remove 3T3 fibroblasts. Cells were monitored by 
microscopy, and fibroblasts were detached by gentle tapping and removed by aspiration. 
Plates were washed with PBS and trypsinized and passaged at a 1:30 dilution with 0.25% 
trypsin-EDTA as in the Old method. Cells were cultured with the New method unless 
otherwise noted. 
 
Conditioned medium culture 
The second method of culture used conditioned medium from irradiated 3T3 
fibroblasts instead of an irradiated feeder layer. Normal or tumor cells were passaged and 
maintained on plates with conditioned medium supplemented with either 10 µmol/L or 5 
µmol/L of Y-27632. When cell cultures were 80-90% confluent, they were passaged the 
same way as in the New method, using differential trypsinization with 0.05% trypsin-
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EDTA to remove any human fibroblasts and trypsin-EDTA to detach and collect cells. 
Cells were passaged at a 1:30 split ratio on to new 60mm plates. 
Media for all cultures was changed every 2 to 3 days. 
 
Conditioning Media 
 Two different methods were used to condition media. In early experiments, we 
seeded multiple 60 mm dishes with 200,000 irradiated 3T3 fibroblasts each in F media. 
Cultures were kept at 37°C and 3% O2. After 48 hours, media was collected off plates 
and filter-sterilized with a 0.45 µm pore-size syringe filter. Conditioned medium was then 
diluted with fresh F media at a 1:2, 1:4, or 1:8 dilution and stored at -20°C. 
 Following the Schlegel group’s publication showing the use of conditioned 
medium in the Georgetown Method (Palechor-Ceron et al. 2013), we adopted their 
protocol for conditioning media. Several 150 mm culture dishes were each plated with 
1.5 million irradiated 3T3 fibroblasts in 30 ml F media and maintained at 37°C and 3% 
O2. Conditioned medium was collected after 48 hours, and three volumes of conditioned 
medium were mixed with one volume of fresh F media. The mixture was then filtered 
with a 0.22 µm pore-size bottle-top filter and stored at 4°C. F media was replaced on the 
plated fibroblasts, and conditioned medium was collected after another 48 hours. Three 
volumes of this conditioned medium were mixed with one volume of fresh F media, and 
the mixture was also filtered with a 0.22 µm pore-size bottle-top filter. This conditioned 
medium was combined with the conditioned medium mixture stored at 4°C, aliquoted, 
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and frozen down at -20°C. The conditioned medium mixture was thawed in a 37°C water 
bath and supplemented with 5 µmol/L Y-27632 prior to use. 
 
MEF Replacement 
 Irradiated 3T3 fibroblasts have a limited lifespan so must be replaced regularly to 
support the cell culture. In the New method, the feeder layer was replaced every six to 
seven days. Irradiated 3T3 fibroblasts frozen in liquid nitrogen were thawed at 37°C, 
washed with F media, and resuspended in the appropriate media. Old fibroblasts were 
removed from the plate using differential trypsinization. Following the PBS wash, the 
resuspended fibroblasts were plated directly on to the plate. Fibroblasts attached to the 
plate in a few hours at 37°C. 
 
Cryopreservation of Cells 
 Cells were frozen down at each passage. Following trypsinization and passaging 
of cultures, remaining cells were spun down at 1000 RPM for 5 minutes and resuspended 
in F media supplemented with 10 µmol/L of Y-27632 and 5% DMSO (Fisher Scientific). 
Cells were then aliquoted in to 1.5 ml cryogenic tubes and stored at -80°C before being 
transferred to liquid nitrogen. When samples were needed, cells were thawed at 37°C, 
washed with F media supplemented with 10 µmol/L of Y-27632, spun down at 1000 
RPM, resuspended in F media supplemented with 10 µmol/L of Y-27632, and plated on 
to an irradiated feeder layer or into conditioned medium. 
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Protein Analysis 
 At each passage of human foreskin keratinocytes, proteins were extracted with 
RIPA lysis buffer [150 mM NaCl, 1.0% NP-40, 0.5% DOC, 50 mM Tris (pH 8.0)] 
supplemented with protease inhibitors Complete (Roche). Extracts were resolved on 
NuPAGE SDS-polyacrylamide 4-12% gradient gels (Invitrogen) in MES SDS buffer 
(Life Technologies), semi-dry electro-transferred to Immobilon PVDF membranes 
(Millipore), and incubated with indicated antibodies before detection by 
chemiluminescence with Western Lighting Plus ECL (PerkinElmer). Antibodies for 
Western include anti-p16, monoclonal antibody JC8 (a gift from James Koh, Department 
of Surgery, Duke University Medical Center. Durham, NC) and actin, monoclonal 
antibody pan Ab-5 (Neomarkers).	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RESULTS 
Initial attempts using Georgetown Method show need for optimization 
 
 The Schlegel group reported success in culturing 88% of tested tissues, which 
included normal and neoplastic cells from a variety of animal tissues (Suprynowicz et al. 
2012). To test whether we could achieve similar success, the Georgetown Method was 
applied to cells from several patient-derived head and neck cancers collected over several 
months. Following dissociation, cells were plated in F medium containing 10 µmol/L Y-
27632 with irradiated mouse fibroblasts. In our initial attempts, we saw limited success. 
Of the 109 tissues tested initially, less than 30% of cultures were passaged for 20 
population doublings or more and less than 5% reached 50 population doublings, the 
standard the Schlegel group used to consider a culture immortalized (Table 2). 
The limited proliferation seen during initial attempts of conditionally 
immortalizing primary tumor-derived cells indicated a problem in our application of the 
Georgetown Method. We considered several possibilities for our failures. First, we 
verified all our reagents corresponded to those of the Schlegel group including media, 
mouse embryonic fibroblast strain, and ROCK inhibitor. We also standardized our 
irradiation protocol to ensure fibroblasts were receiving an appropriate amount of 
radiation to induce DNA-damage arrest. Mouse fibroblasts undergoing earlier rounds of 
irradiation may have been overdosed with greater than 3000 rads. Once we confirmed 
these factors, we then sequentially tested several factors including ROCK inhibitor 
stability, fibroblast survival, differential trypsinization, and oxygen levels in culture to 
determine whether one or more of these factors was responsible for our limited successes. 
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Table 2. Culture efficacy of Georgetown Methods. Initial attempts of using the 
Georgetown Method, the “Old” protocol, resulted in less than 5% of cultures reaching 50 
population doublings (PD). Differential trypsinization and feeder layer replacement in the 
“New” and “Rescue” protocols improved immortalization efficacy significantly. The 
majority of tissues tested were OPSCC, but tested samples also include normal tonsil 
epithelium and foreskin keratinocytes. 
 
	  	   Old	   Rescue	   New	  
Number	  of	  samples	  tested	   109	   13	   12	  
Cultured	  >=10	  PD	   42.2%	   100.0%	   91.7%	  
Cultured	  >=20	  PD	   28.4%	   100.0%	   91.7%	  
Cultured	  >=30	  PD	   14.7%	   100.0%	   91.7%	  
Cultured	  >=40	  PD	   9.2%	   100.0%	   83.3%	  
Cultured	  >=50	  PD	   4.6%	   76.9%	   83.3%	  
 
 
Differential trypsinization and regular feeder layer replacement resolve senescence 
Our lab regularly used a 1:30 split ratio for passaging because each passage was 
thus equivalent to approximately 5 population doublings. Upon review of the Schlegel 
group methods, we noticed that their group passaged cells at split ratios anywhere from 
1:4 to 1:32, but the majority of their figures show cells being passaged every three to four 
days at split ratios of 1:8 or 1:16 with cells, two to four times greater than our 1:30 split 
ratio (Table 3). We also noted that the Schlegel group differentially trypsinized plates 
with versene or 0.05% trypsin to remove the fibroblast feeder layer before passaging 
tumor-derived cells on to fresh fibroblasts (Table 3). 
Although most of our tumor samples reached the 80-90% confluence necessary 
for passaging within one week during early passages, our lower plating density resulted 
in slower-growing cultures remaining on the plate for up to two weeks before achieving 
appropriate confluence. After extended time on the plate, irradiated fibroblasts appeared 
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sickly with large vacuoles and non-uniform phenotypes, an indication of apoptosis. 
Replating of senescing PTDC on to a fresh fibroblast feeder layer sometimes resulted in 
rescue and continued growth. This led us to two hypotheses. 
One hypothesis was that old irradiated fibroblasts stop producing a factor 
necessary for conditional immortalization. Differential trypsinization was not used during 
initial attempts, potentially allowing older fibroblasts to be passed on to successive 
cultures during passaging. A second and more likely hypothesis was that older fibroblasts 
are releasing factors into the media that inhibit growth. The combination of extended 
culturing without fibroblast replacement and passaging without differential 
trypsinization, referred to as our “Old” method, could contribute to the early senescence 
seen in our initial attempts of conditional immortalization (Table 2, Table 3). 
Table 3. Comparison of Georgetown Methods. Our New method adopted differential 
trypsinization of the feeder layer before passaging of CRCs and weekly feeder layer 
replacement. Feeder layer replacement compensated for the extended time between 
passages due to the lower split ratio. 
 
 Schlegel Method Old Method New Method 
Culture oxygen 
levels 
21% 3% 3% 
Media change 
 
Every 2-3 days Every 2-3 days Every 2-3 days 
Passaging split 
ratio 
1:4 to 1:32 (mostly 
1:8 and 1:16) 
1:30 1:30 
Passaging 
frequency 
Every 3-5 days Every 7-14 days Every 7-14 days 
Differential 
trypsinization 
With 0.05% trypsin 
or versene 
None With 0.05% trypsin 
Feeder layer 
replacement 
None reported None Every 7 days 
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With an adoption of differential trypsinization during passaging and replacement 
of the fibroblast feeder layer every seven days, our modified Georgetown Method, 
referred to as our “New” method, was applied to early-passage (5 population doublings) 
primary human foreskin keratinocytes (HFK) (Table 3). The Schlegel group first showed 
the ability of the Georgetown Method to conditionally immortalize cells in primary 
keratinocytes (Chapman et al. 2010). With our new protocol, we successfully cultured the 
HFK cells for 100 population doublings for a period of 138 days (Figure 2). The growth 
rate remained stable throughout, corresponding to the results seen by the Schlegel group. 
Culture on the feeder layer only without the ROCK inhibitor resulted in senescence of 
HFK cells after 45 population doublings. Removal of the ROCK inhibitor from HFK 
cultures that were initially grown with both the ROCK inhibitor and feeder cells induced 
senescence within 15 population doublings after the switch. 
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Figure 2: Differential trypsinization and feeder layer replacement supports growth 
of foreskin keratinocytes. Human foreskin keratinocytes (HFK) were cultured for 100 
population doublings using the Georgetown Method. HFKs cultured without the ROCK 
inhibitor senesced after 45 population doublings. Removal of the ROCK inhibitor 
induced senescence after 15 population doublings. 
 
The ability of our revised protocol to support long-term cultures of HFK 
suggested that regular replacement of the feeder layer and removal of fibroblasts with 
differential trypsinization prior to passaging could improve our efficacy in culturing 
primary head and neck specimens. Thawing out early-passage (5 population doublings) 
cells that previously senesced under our Old method after 20 to 30 population doublings, 
we also showed that our modified system supports the conditional immortalization of 
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many types of specimens, including OPSCC (T/B), normal tonsilar epithelium (NT), and 
foreskin keratinocytes (HFK) (Figure 3). Frozen stocks of cells that were thawed and 
regrown using the modified protocol successfully bypassed previous points of 
senescence. 
 
Figure 3: Modified protocol resolves senescence previously seen during initial 
attempts of using Georgetown Method. Application of our modified New Georgetown 
Method to OPSCC (T/B), human foreskin keratinocytes (HFK), and normal tonsilar 
epithelium (NT) allows cultures to bypass previous points of senescence seen under the 
Old system by 15 population doublings or more. Arrow indicates cultures are still 
growing and being passaged. 
 
While less than 5% of cultures under our Old system were able to reach 50 
population doublings, greater than 80% of cultures grown under the modified system 
were successfully immortalized (Table 2). Some cultures were also grown with a 
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“Rescue” method in which they were initially grown with the Old method but switched 
over to the New method during their passaging. Over 75% of these cultures also reached 
50 population doublings, suggesting potential of the New method to rescue senescence 
(Table 2).  
Three late-passage OPSCC samples were also thawed 10 population doublings 
prior to their previous points of senescence under the Old system and cultured under the 
New system. Because these cultures were grown with the Old system during early 
passages and thawed into the New system, they are considered to be grown under the 
Rescue method. All three of these cultures were propagated past their previous points of 
senescence, but two of the three cultures, T/B 75 and T/B 81, eventually senesced (Figure 
4). 
Overall, there was a significant increase in survival with the New system 
compared to the Old system, with over 80% of tissues cultured with the New system still 
propagating at least 50 population doublings (Figure 5). 
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Figure 4: OPSCC cultures grown under the Rescue method pass previous 
senescence points but some eventually senesce. OPSCC culture T/B 75 (A), T/B 80 
(B), and T/B 81 (C) were thawed 10 population doublings prior to their previous 
senescence points under the Old system. Applying differential trypsinization and regular 
fibroblast replacement, all passed senescence points seen under the Old system, but T/B 
75 and T/B 81 eventually senesced. T/B 80 continued propagating and was effectively 
immortalized. 
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Figure 5: Differential trypsinization and MEF replacement results in significantly 
increased survival of cultured tissues. Less than 5% of tissues cultured under the Old 
method reached 50 PD, but about 80% of tissues cultured under the New system 
successfully did. Tissues cultured under the Rescue method had slightly lower long-term 
survival than the New method but still had significantly higher survival than the Old 
method. 
 
 
ROCK inhibitor loss is not likely cause of limited PTDC survival 
 In addition to the fibroblast feeder layer, the ROCK inhibitor is an integral player 
in cellular immortalization. Degradation or decreased efficacy of the ROCK inhibitor 
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over time could hinder immortalization of cell cultures. Culture media is changed every 
two to three days, and the ROCK inhibitor is added to F media either the day of or day 
before use. Y-27632 has a half-life of 12 to 16 hours in serum, so it may lose its efficacy 
by the time the media is used (Ishizaki et al. 2000). However, because Y-27632 is known 
to be an irreversible inhibitor, the ROCK pathway will still be inhibited even if Y-27632 
is removed from culture. The ROCK pathway will become activated again only after cells 
undergo replication.  
We decided to examine the efficacy of the ROCK inhibitor in culture and whether 
its short half-life could affect cell culture growth. OPSCC cultures were grown either 
with F media supplemented with ROCK inhibitor no more than one day before use 
(Normal ROCKi), which duplicates our initial attempts of applying the Georgetown 
Method; F media supplemented with ROCK inhibitor immediately before use of the 
media (Fresh ROCKi); or 10 uM of ROCK inhibitor was added to the culture every day 
(Everyday ROCKi). We saw no significant difference in growth between the three ROCK 
inhibitor conditions in supporting growth of OPSCC T/B 75 and T/B 81 (Figure 6). These 
results suggest that the ROCK inhibitor remains stable enough in culture to support 
immortalization of OPSCC and/or intermittent ROCK inhibitor exposure is sufficient to 
induce immortalization. It also decreases the likelihood that the loss of ROCK inhibitor 
was the cause of early difficulties to conditionally immortalize cells using the 
Georgetown Method.  
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Figure 6: Old method ROCK inhibitor conditions are sufficient to support 
immortalization through Georgetown Method. OPSCCs T/B 75 (A) and T/B 81 (B) 
cultures were grown in either F media supplemented with Y-27632 no more than one day 
before use (Normal ROCKi), F media supplemented with Y-27632 immediately before 
use (Fresh ROCKi), or supplemented with Y-27632 directly into the culture every day 
(Everyday ROCKi). No significant difference in growth was observed between the 
ROCK inhibitor conditions. 
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Conditional immortalization is supported at physiological and atmospheric oxygen 
 
 Cell culture at physiological oxygen levels (3%) is known to increase plating 
efficiency and lifespan of cultured cells relative to cell culture at atmospheric oxygen 
levels (21%) (Richter, Sanford, and Evans 1972; Packer and Fuehr 1977; Parrinello et al. 
2003). We questioned whether oxygen levels affected the efficacy of conditionally 
immortalizing co-cultured cells. Our initial attempts of applying the Georgetown Method 
were conducted at physiological oxygen (3%), but use of our modified Georgetown 
Method on early-passage HFK cultures showed similar steady growth in both 
physiological and atmospheric oxygen (Figure 7A).  
Tumor cells frozen down after extended passaging at 3% oxygen under our Old 
system were thawed 10 population doublings before their previously observed senescence 
point and grown with our modified protocol at both physiological and atmospheric 
oxygen. Cultures grown at 3% oxygen surpassed the previous senescence point, but 
cultures grown at 21% oxygen senesced 10 population doublings after thawing and 
plating (Figures 7B, 7C, 7D). Because cells were grown at 3% oxygen at early passages, 
the early selection of cells that thrive better at physiological oxygen could impact their 
survival when switched over to growth in atmospheric oxygen. Keratinocytes we cultured 
were thawed from low-passage cultures, limiting the selection of cells by culture 
conditions. Support of HFK growth in both 3% and 21% oxygen with our New system 
suggests that the Georgetown Method is equally effective at both physiological and 
atmospheric oxygen levels. 
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Figure 7: Low-passage HFKs are immortalized in both physiological and 
atmospheric oxygen but high-passage OPSCCs are immortalized at only 
physiological oxygen. Low-passage HFK cultures (5 PD) grown at 3% and 21% oxygen 
showed similar rates of growth (A). Thawed high-passage OPSCC cultures of T/B 75 
(B), T/B 80 (C), and T/B 81 (D) initially cultured at 3% oxygen were successfully grown 
at 3% oxygen but senesced when cultured at 21% oxygen. 
 
Conditioned medium can substitute for direct co-culture with feeder layer to 
support immortalization 
 The ability of our New method, which adopts differential trypsinization and 
feeder layer replacement, to support immortalization of cultured cells suggest that old 
fibroblasts fail to support conditional immortalization and/or have a detrimental effect on 
co-cultured cells. The Schlegel group recently reported that direct co-culture with 
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irradiated fibroblasts is not necessary for the Georgetown Method to work, and media 
conditioned by irradiated fibroblasts can be used instead to immortalize cells (Palechor-
Ceron et al. 2013). Eliminating the need to differentially trypsinize during passaging and 
replace fibroblasts regularly would make the process of immortalizing cells more 
efficient and effective. We decided to test whether conditioned medium from irradiated 
fibroblasts could immortalize OPSCC and normal tonsil epithelium as effectively as 
direct co-culture with a feeder layer. Rather than studying HFKs, we decided to study 
normal tonsil epithelium because it is more similar to the OPSCC we are interested in. 
During our initial tests, irradiated fibroblasts were plated in F media and allowed 
to condition the media for 48 hours before harvesting and filter sterilizing the media. 
Conditioned medium was then diluted with unconditioned F media to different ratios to 
compare the efficacy of lower dilutions of conditioned medium to support 
immortalization. All media was supplemented with 10 uM of Y-27632. We observed that 
all concentrations of conditioned medium resulted in comparable rates of growth to direct 
co-culture with irradiated fibroblasts over 35 population doublings (Figure 8A). This 
shows that conditioned medium diluted to as low as 1:8 can substitute for direct co-
culture with a feeder layer. Whether there is a difference in growth over a longer period 
of time between the varying concentrations of conditioned medium remains to be 
determined. 
 Following our initial conditioned medium tests, the Schlegel group recently 
published a paper detailing their methods of conditioning media (Palechor-Ceron et al. 
2013). For later conditioned medium tests, we decided to apply their findings: 
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conditioning media over 96 hours rather than 48 hours, using a 3:1 dilution of 
conditioned medium to unconditioned F media for cell culture, and supplementing 
conditioned medium with 5 uM of Y-27632. We have compared the efficacy of 
conditioned medium to fibroblast co-culture for several tissues including 6 OPSCC 
samples using our initial media conditioning method and 3 OPSCC and 2 normal tonsilar 
epithelium samples using the Schlegel media conditioning method. We found that 
conditioned medium can support culture growth as well as direct co-culture in all samples 
tested (Figure 8B, 8C, 8D).  
The ability of conditioned medium to immortalize cells without co-cultured 
fibroblasts, the cause of our initial limited success with the Georgetown Method, is a 
novel finding that eliminates the need for differential trypsinization and feeder layer 
replacement. Conditioned medium will allow us to more easily conduct high-throughput 
screens, including DNA sequencing and chromatin immunoprecipitation (ChIP), without 
the otherwise necessary step of separating tumor-derived cells from co-cultured 
fibroblasts. 
	  50	  	  
 
 
Figure 8: Conditioned medium supports OPSCC and NT growth as effectively as 
direct co-culture with irradiated fibroblasts. Dilutions of conditioned medium (CM) as 
low as 1:8 were just as effective as fibroblast direct co-culture in supporting OPSCC T/B 
99 growth (A). CM was able to support growth of OPSCC T/B 41 (B) and two different 
cultures of normal tonsilar epithelium as effectively as a fibroblast feeder layer (C, D). 
All CM was supplemented with Y-27632.  
 
 
ROCK inhibition maintains low p16 expression at low passages 
 Although the mechanism of how the Georgetown Method conditionally 
immortalizes co-cultured cells is currently unknown, we have found evidence that the 
ROCK inhibitor may contribute to conditional immortalization of cells through p16 
regulation. Low-passage (5 PD) HFK cells were thawed and plated on an irradiated 
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feeder layer in either F media or F media supplemented with Y-27632. These cells were 
maintained in both 3% and 21% oxygen, and cell lysates were collected at each 
passaging. 
p16 is known to tightly regulate the cell cycle and cellular senescence, but the 
mechanism of its regulation is still not understood. We found that at relatively low 
passages (20-35 PD) with the Georgetown Method, HFK p16 expression was maintained 
at low levels while HFKs cultured without the ROCK inhibitor showed a gradual increase 
in p16 expression (Figure 9A). Because atmospheric oxygen levels are known to induce 
stress and senescence in cell culture, we also tested whether ROCK inhibition could 
maintain p16 expression at low levels in 21% oxygen in addition to 3% oxygen. Similar 
patterns of p16 expression seen in cultures grown at 3% oxygen were also seen at 21% 
oxygen (Figure 9A).  
HFK cultures grown on an irradiated feeder layer without the ROCK inhibitor 
senesced after 40 population doublings, but HFK cultures grown on an irradiated feeder 
layer with the ROCK inhibitor were maintained for over 100 population doublings and 
effectively immortalized at both 3% and 21% oxygen (Figures 2, 7A). At higher passages 
of HFK cultures, we saw that p16 expression gradually began increasing around passage 
13 (65 PD), despite being cultured with the ROCK inhibitor (Figure 9B). Even with 
increasing p16, cultures continued to maintain a steady growth rate at these higher 
population doublings and showed no phenotypic signs of senescence (Figure 7A). 
Our preliminary data suggests that ROCK inhibition may prevent senescence by 
maintaining p16 levels during low passages. However, the increase in p16 expression at 
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later passages suggests that ROCK inhibition may also be acting through additional 
pathways besides p16 such as p21 and p53 to maintain the proliferative ability of the 
culture. Further research is needed to understand how ROCK inhibition can maintain p16, 
why p16 increases during later passages, and p16’s mechanism of regulation. 
 
 
 
Figure 9: ROCK inhibition maintains low p16 levels in low-passages but not at 
higher passages. At low passages (20-35 PD), HFKs grown with Y-27632 maintained 
low p16 levels in both 3% and 21% oxygen, but HFKs grown without Y-27632 had 
increasing p16 expression (A). p16 levels of HFKs cultured with Y-27632 increased after 
about 65 PD and remained relatively high even as HFKs continued proliferating for 100 
PD (B). 
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DISCUSSION 
This study has optimized the use of the Georgetown Method for the culture of 
head and neck cancers and begun to investigate its mechanism to conserve the replicative 
potential of cultured cells. Our findings show that differential trypsinization and regular 
feeder layer replacement can resolve the limited survival of tumor-derived OPSCC cells 
seen in our earlier attempts to conditionally immortalize tumor-derived cells with the 
Georgetown Method. Our application of the Georgetown Method has achieved 
comparable levels of success to those seen in the Schlegel lab in the immortalization of 
both normal and neoplastic cells. 
  
P16 PATHWAY AND EPIGENETIC MARKS 
However, a fifth of tested tissues failed to be cultured using this method, results 
similar to those obtained by the Schlegel group. Why particular tumor specimens of 
different tissues are not immortalized is currently unknown, but identifying the common 
characteristics of these tissues could lead to important discoveries about the mechanism 
of the Georgetown Method and eventual chemotherapeutics that target these pathways to 
prevent immortalization of cancer cells in vivo. Because the majority of our samples was 
OPSCC and tested for HPV, we examined HPV status of our samples, but our 
preliminary analysis saw no correlation between HPV status and CRC failures.  
After identifying the problems of our Old method, we found that some cultures 
initially cultured without differential trypsinization and fibroblast replacement during 
early passages and switched over to our New method in later passages (labeled as Rescue 
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cultures) still senesced but at later passages than those seen during the Old method. While 
our New method supported growth of over 80% of tested tissues, a lower proportion of 
tissues cultured with the Rescue method were successfully immortalized.  
Our findings that the ROCK inhibitor in culture maintains low p16 levels in early 
passages suggest a potential role of p16 in the mechanism of the Georgetown Method. 
The p16INK4A pathway is known to regulate cell cycle progression and senescence, 
preventing damaged cells from inappropriately dividing. Our lab recently reported that 
the C-terminal binding protein (CtBP), a target in many stress-signaling pathways, plays 
an important role in p16 regulation and senescence (Mroz et al. 2008). CtBP potentially 
links various cellular stresses to senescence seen in primary cells via the p16 pathway. 
The p16 promoter is also known to be “bivalent” and shows the potential to “resolve” 
epigenetically to a repressed or activated state, which can be passed on to progeny to 
affect their sensitivity to stress signals (Bernstein et al. 2006; Mikkelsen et al. 2007). 
Early culture stresses caused by the Old method could set early epigenetic marks for 
senescence that remain irreversible even when tumor-derived cell cultures are switched to 
more favorable culture conditions in later passages. This could explain the decreased 
survival of Rescue cultures compared to New cultures, and early cellular stresses could 
contribute to the observed senescence of a fifth of tested tissues. Favorable conditions 
under the New method may not be enough to reverse these epigenetic marks. Our 
findings suggest that the ROCK inhibitor may help preserve the bivalency of p16 to 
maintain the replicative potential of tumor-derived cells. However, further research is still 
	  55	  	  
needed to fully understand how the Georgetown Method prevents senescence, through 
p16 and possibly additional senescence pathways such as p14ARF, p21, and p53. 
 
CONDITIONED MEDIUM AND TUMOR MICROENVIRONMENT 
The ability for conditioned medium to substitute for direct co-culture with an 
irradiated fibroblast feeder layer effectively eliminates the previous problems caused by 
old fibroblasts including the lack of a diffusible factor necessary for growth and/or an 
inhibitory factor released by old fibroblasts. The only problem we observed when using 
conditioned medium is potential outgrowth of human fibroblasts in culture since growth 
of human fibroblasts is suppressed by co-culture with an irradiated fibroblast feeder 
layer. Because human fibroblasts generally proliferate at a faster rater than keratinocytes, 
growth in conditioned medium may result in overgrowth of human fibroblasts. However, 
differential trypsinization can be used to selectively remove human fibroblasts from the 
plate. 
Culturing with a fibroblast feeder layer requires separation of primary cells from 
co-cultured fibroblasts before primary cells can be analyzed. The ability to culture 
primary cells with conditioned medium instead and without an irradiated fibroblast feeder 
layer would be very useful for high-throughput screens by making them faster and their 
results more reliable. It completely eliminates the need to separate primary cells from 
fibroblasts in culture before analysis is done. DNA sequencing or ChIP, for example, will 
be much easier and more accurate without the presence of mouse fibroblasts to 
contaminate samples and skew results. 
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The fact that irradiated fibroblasts release a diffusible factor that can conditionally 
immortalize cells in the presence of a ROCK inhibitor also provides clues to the 
mechanism of the Georgetown Method and information about how cancer may be 
regulated. There recently has been an increased focus on understanding the tumor 
microenvironment and its impact on tumor progression. Rather than just a homogenous 
mass of cells, tumors have high heterogeneity, and specific cells within the tumor niche 
could release diffusible growth factors necessary for the overall tumor to grow and 
proliferate. One compelling hypothesis for why less than 5% of tumors can form cell 
lines is that culture conditions fail to model the complexity of the tumor 
microenvironment. Irradiated fibroblasts in conjunction with the ROCK inhibitor may be 
recapitulating the tumor niche in vitro by releasing factors usually released by other cells 
in the tumor microenvironment necessary for tumor growth.  
The Schlegel group found that only irradiated, senescent fibroblasts release 
diffusible factors necessary to immortalize co-cultured cells. As our cells age, our tissue 
niche may also change as older cells senesce, and these senescent cells may release 
factors that promote neoplastic cell growth, ultimately increasing the risk of cancer. If we 
can identify the factors that support cancer cell proliferation, we may be able to use them 
as future chemotherapeutic targets to regulate the tumor niche. 
 
ONGOING AND FUTURE WORK 
The ability to culture over 80% of our tested tissues for over 50 population 
doublings allows us to accomplish many of our goals using TDCL. Rather than testing 
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therapies or elucidating cellular pathways using established cell lines, which represent 
less than 5% of all cancers, we can significantly increase inter-tumor heterogeneity of our 
experimental models by creating a huge library of tissues from which to study. Use of 
these tissues has the potential to make huge strides in our understanding of 
immortalization and senescence, the tumor microenvironment, translational in vitro 
models, and viable biobanking. 
 
UNDERSTANDING THE TUMOR MICROENVIRONMENT 
The limited number of tumors that do form cell lines without the Georgetown 
Method could be doing one of two things: they could either be niche-independent, 
possessing mutations that allow them to grow despite the absence of diffusible growth 
factors in cell culture, or they could have an autocrine signaling pathway, regulating their 
own growth through release of growth factors from the same cell. Currently, we are 
testing the latter hypothesis and examining whether conditioned medium from established 
cell lines contain a diffusible factor similar to that released by the feeder layer that can 
immortalize cells in culture.  
 
TRANSLATIONAL ASSESSMENT OF TUMOR-DERIVED CELLS 
Besides understanding the mechanism of the Georgetown Method, we are 
especially interested in assessing the translational value of cultures derived this method. 
Through genome-wide analysis, PDX models have been shown to conserve mutations, 
genomic features, and relative clonal diversity (Li et al. 2013). Because most OPSCC 
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tumors are small and cell numbers are insufficient for creating PDX models, expansion of 
cells through the Georgetown Method provides a means to culture enough cells for future 
xenografts.  
Now that we are able to reliably expand primary tumor-derived cells with this 
method, one of our ongoing projects is to compare BH3 profiles of the primary tumor, 
tumor-derived cultures, and murine xenografts to determine how well tumor-derived cell 
cultures model the original tumor. BH3 profiling is a method to predict cellular fate 
decisions via measurements of responses to stimulation of various parts of the apoptotic 
pathway (Moore and Letai 2013). By looking at BH3 profile differences, we can make 
predictions about the chemosensitivity of a given population of cells and observe how the 
cell population changes throughout the culturing process (Figure 10). If populations of 
PTDC have similar BH3 profiles to their original corresponding tumors, this suggests the 
Georgetown Method conserves the cellular diversity and characteristics of the original 
tumor during expansion, making tumor-derived cell lines representative tumor models for 
future clinical applications. We can also investigate whether intratumor heterogeneity is 
conserved throughout the expansion process, especially after long-term passaging, or 
whether specific clones are selectively immortalized. Ideally, similar signals between the 
tumor and tumor-derived cultures would indicate a high degree of translatability for 
future drug screens, drug testing, and cancer studies.  
Cell culture conditions often select for subpopulations of cells, and with increased 
passaging, heterogeneity decreases as the fastest growing cells outcompete slower 
growing cells. Xenografts are known to preserve the heterogeneity of the original tumor 
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fairly well, but the heterogeneity of cultures grown with the Georgetown Method is 
currently unknown. Our finding that the Georgetown Method maintains low p16 
expression suggests maintenance of p16 bivalency to keep cells in a stem cell-like state 
that preserves their replicative potential. Whether a large majority of cells retain the 
capacity to divide or whether a subpopulation of cancer stem cells is maintained has yet 
to be determined. Following expansion of the tumor-derived cell cultures, we are also 
creating xenografts examine whether heterogeneity of the original tumor is conserved in 
xenografts and whether xenografts differ significantly from cell cultures. We can thus 
begin to determine the quality and applicability of tumor-derived cell cultures and 
subsequent xenografts as an appropriate model for cancer research. 
 
 
Figure 10: Translational assessment of PTDC with BH3 profiling. By comparing 
BH3 profiles of the primary tumor, resultant CRCs, and mouse xenograft, we can observe 
how the cell population changes throughout the conditional immortalization process. 
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TISSUE BIOBANKING 
Because we have developed the ability to expand tumor-derived cells consistently 
with our New method, we can return to early-passage frozen stocks of tumor-derived 
cells for expansion. With currently over 120 different OPSCC tissue specimens collected, 
we have begun to form a biobank of tissues through systematic expansion and 
cryopreservation of each specimen (Figure 11). However, there are several issues we 
must consider as we begin biobanking of primary tumor-derived cells. 
Because tumors may contain a variety of cell types including normal epithelial 
cells and endothelial cells in addition to the neoplastic cells, we must verify whether our 
expanded cultures contain the tumor cells we are trying to study. The Georgetown 
Method supports cultures of both normal and neoplastic cells, creating the risk that 
certain cell types could outcompete others because of faster growth in culture. Our initial 
plan of attack to distinguish between these cell types has several approaches. First, 
xenografts will be created from cell cultures to ensure they contain neoplastic cells. In 
our preliminary xenograft tests with one normal tonsil epithelium specimen and two 
tumor-derived cell specimens, we saw that normal epithelium did not form a tumor 
whereas the tumor-derived cells did as we expected. However, further samples will need 
to be tested to verify the reliability of xenografts to distinguish between normal and 
neoplastic tissues. Besides xenografts, we will also use cell markers for identification. 
Because the majority of our samples are HPV-positive, we will use antibodies against 
p16 to identify HPV-positive tumor cells and markers like VE-Cadherin and CD31 to 
distinguish between endothelial cells and tumor cells. PCR amplification of E6/E7 RNA 
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transcripts will also identify HPV-positive cells, and karyotyping will identify aneuploidy 
or other chromosomal abnormalities not present in normal cells. 
 The sheer number of patient specimens also holds the risk of cross-contamination 
between cultures. Before drug testing or drug screening, we must also validate that tumor 
cultures correspond to cells from the correct patients. Short Tandem Repeat (STR) 
analysis is the gold standard for cell-line validation, and we can apply this technique to 
the original tumor, tumor-derived cell cultures, and xenografts. Analyzing STR profiles at 
all three points of expansion will ensure that our tumor-derived cell lines stay consistent 
throughout our expansion process. Our biobank also consists of blood samples for each 
patient that can be used for future sequencing. 
With our large number of patient samples, we must systematically expand and 
preserve these cells to create a reliable stock for future validation, experiments, and 
xenografting. Following initial dissociation of primary tumors, cells were expanded to 
about 5 population doublings in culture before being collected and frozen down in liquid 
nitrogen. Our plan is to expand these initial freezedowns to derive a stock of about 20 
million cells per specimen at 10 population doublings that can be thawed and used for 
procedures including xenografts and validation assays. We have already begun expansion 
of several of our tumor-derived cell specimens, particularly ones with BH3 profiling data 
for the original tumor to initiate BH3 profile comparisons between the tumor, cell culture, 
and xenografts. With our biobank, we will ultimately be able to thaw and expand frozen 
cells easily with the Georgetown Method for future studies on OPSCC and other primary 
tumor-derived cells. 
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Figure 11: Biobanking and validation plan for primary tumor-derived cells. Primary 
tumor cells were initially dissociated, expanded 5 population doublings, and frozen down 
in liquid nitrogen. These stocks will be expanded to 10 population doublings, yielding a 
general stock of about 20 million tumor-derived cells for future validation, xenografts, 
and other experiments. Cells will continue to be maintained, passaged, and frozen down 
every 5 population doublings. 
 
The ability to culture over 80% of primary tumors with the Georgetown Method 
is a powerful tool that can revolutionize future cancer research. It allows scientists to 
move past the limits on inter-tumor heterogeneity that current cell lines have on research 
and begin studying tumor biology with more representative primary tumor-derived 
models. The Georgetown Method also provides a technique to expand cells from small 
tumors like those seen in OPSCC or early-stage melanoma whose small specimen sizes 
have limited characterization, diagnostics, and treatments. We can expand on our 
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understanding of how the diversity of cell types within a tumor can impact the tumor 
microenvironment and take advantage of these discoveries to find targets for new 
chemotherapeutics. Tumor-derived cells also have the potential to be a novel clinical tool 
for diagnostics and testing of tumor drug resistance, already shown to be effective for a 
case of recurrent respiratory papillomatosis. Because p16 is inactivated at early stages of 
tumor development for nearly all cancers, the potential maintenance of low p16 
expression by ROCK inhibition to regulate senescence is an exciting finding that could 
shed light on this important tumor suppressor. Further research is still needed to fully 
understand how the Georgetown Method conditionally immortalizes cells and to evaluate 
the translational value of CRCs to the clinic. 	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